Indication
Stomach Squamous Cell Carcinoma
2 clinical trials
1 product
2 drugs
Clinical trial
Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal EffectStatus: Completed, Estimated PCD: 2022-01-20
Product
PembrolizumabClinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Drug
LurbinectedinDrug
T-VEC